INT 767

Drug Profile

INT 767

Alternative Names: Dual FXR/TGR5 agonists - Intercept Pharmaceuticals; FXR & TGR5 BA-derived backups - Intercept Pharmaceuticals; INT-767

Latest Information Update: 15 May 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Intercept Pharmaceuticals
  • Class Anti-inflammatories; Antifibrotics; Bile acids and salts; Cholanes; Hepatoprotectants; Small molecules; Sulfates
  • Mechanism of Action Farnesoid X-activated receptor agonists; G protein-coupled receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Hepatic fibrosis
  • Preclinical Non-alcoholic steatohepatitis
  • No development reported Diabetic nephropathies; Metabolic disorders

Most Recent Events

  • 11 Apr 2018 Pharmacodynamics data from a preclinical trial in Firbosis presented at the International Liver Congress 2018 (ILC-2018)
  • 28 Jan 2018 No recent reports of development identified for preclinical development in Diabetic-nephropathies in USA (PO)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Metabolic-disorders in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top